🇺🇸 FDA
Patent

US 11542526

Oncolytic adenoviral vector and methods of use

granted A61KA61K35/761A61K45/06

Quick answer

US patent 11542526 (Oncolytic adenoviral vector and methods of use) held by Unleash Immuno Oncolytics, Inc. expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Unleash Immuno Oncolytics, Inc.
Grant date
Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K35/761, A61K45/06, A61K48/00, A61P